Drug Type Small molecule drug |
Synonyms 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine + [1] |
Target |
Mechanism mGluR2 positive allosteric modulator(Metabotropic glutamate receptor 2 positive allosteric modulator) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC22H22F5N5 |
InChIKeyBNJUYVSEWGRELC-UHFFFAOYSA-N |
CAS Registry1254979-66-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Diseases | Preclinical | BE | 09 Sep 2016 | |
Central Nervous System Diseases | Preclinical | ES | 09 Sep 2016 | |
Schizophrenia | Preclinical | US | - |